NUWONDER

Nuwonder is a clinical-stage biotechnology company based in Shanghai, China, dedicated to developing innovative treatments for rare diseases, with a primary focus on metabolic and neuromuscular disorders. The company leverages its proprietary Nu-In platform, which is designed to overcome the challenges of intracellular delivery for large molecule therapeutics. Its lead asset, NW-001, is a next-generation enzyme replacement therapy (ERT) for Pompe disease that aims to provide superior muscle tissue uptake compared to existing treatments. Nuwonder's pipeline is built on deep expertise in protein engineering and lysosomal biology to address significant unmet medical needs. The firm has successfully raised significant venture capital from top-tier investors like Sequoia China and Matrix Partners to advance its clinical programs. By focusing on optimized delivery mechanisms, Nuwonder seeks to redefine the standard of care for patients suffering from lysosomal storage diseases.